A Study to Assess the Long-Term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder

Back to Search
Print
Bookmark Trial

NCT00635076

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Eugene, Oregon, 97401, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Panic Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
13-17 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- A primary Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision diagnosis of panic disorder with or without agoraphobia based on the Mini-International Neuropsychiatric Interview for Children and Adolescents

- Subjects with an average of 1) at least one 4-symptom panic attack per week over the last 4 weeks before screening; 2) at least one 4-symptom panic attack per week over the last 4 weeks before baseline; and 3) at least one 4-symptom panic attack in the 7 days prior to baseline

- To enter Study A6131007, subjects must have completed Study A6131002, had an acceptable tolerability to study drug, and in the clinical judgment of the investigator, could have benefited from continued study treatment.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Subjects must continue to meet all of the exclusion criteria enumerated in the Acute
Efficacy Study (Protocol A6131002) with the following exception: Subjects will be
allowed to undergo cognitive-behavioral or other panic-specific therapy and any other
psychotherapy (e.g., supportive and/or family therapy) during the expected study
period in this study.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Panic DisorderStudy Evaluating Venlafaxine ER in Adults With Panic Disorder NCT00038896
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Panic DisorderA Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder NCT00677352
  1. Nagoya, Aichi
  2. Fukuoka-shi, Fukuoka
  3. Kitakyushu-shi, Fukuoka
  4. Kitakyusyu-shi, Fukuoka
  5. Sapporo-Shi, Hokkaido
  6. Sapporo, Hokkaido
  7. Higashiibaraki-gun, Ibaraki
  8. Fujisawa-city, Kanagawa
  9. Sagamihara-Shi, Kanagawa
  10. Yokohama-Shi, Kanagawa
  11. Yokohama, Kanagawa
  12. Kawaguchi-shi, Saitama
  13. Saitama city, Saitama
  14. Chiyoda-ku, Tokyo
  15. Kita-ku, Tokyo
  16. Minato-ku, Tokyo
  17. Musashino, Tokyo
  18. Nakano-Ku, Tokyo
  19. Nakanoku, Tokyo
  20. Setagaya-ku, Tokyo
  21. Shinjuku-ku, Tokyo
  22. Toshima-ku, Tokyo
  23. Nakano-ku, Yokohama
  24. Minato-ku,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Panic DisorderStudy Evaluating Venlafaxine ER in Patients With Panic Disorder NCT00044772
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Panic DisorderA Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks NCT00634790
  1. Little Rock, Alaska
  2. Phoenix, Arizona
  3. Scottsdale, Arizona
  4. Burbank, California
  5. Elcentro, California
  6. La Mesa, California
  7. Los Angeles, California
  8. Oceanside, California
  9. San Diego, California
  10. San Marcos, California
  11. Gainesville, Florida
  12. Hialeah, Florida
  13. Jacksonville, Florida
  14. North Miami, Florida
  15. St. Petersburg, Florida
  16. West Palm Beach, Florida
  17. Decatur, Georgia
  18. Boise, Idaho
  19. Schaumburg, Illinois
  20. Terre Haute, Indiana
  21. Overland Park, Kansas
  22. Lexington, Kentucky
  23. Owensboro, Kentucky
  24. New Orleans, Louisiana
  25. New Orleans, Louisiana
  26. Baltimore, Maryland
  27. Clinton Township, Michigan
  28. Saint Paul, Minnesota
  29. Omaha, Nebraska
  30. Las Vegas, Nevada
  31. Clementon, New Jersey
  32. Kenilworth, New Jersey
  33. Morristown, New Jersey
  34. Bismarck, North Dakota
  35. Cleveland, Ohio
  36. Lyndhurst, Ohio
  37. Eugene, Oregon
  38. Bala Cynwyd, Pennsylvania
  39. Hershey, Pennsylvania
  40. Media, Pennsylvania
  41. Columbia, South Carolina
  42. Selmer, Tennessee
  43. San Antonio, Texas
  44. Salt Lake City, Utah
  45. Midlothian, Virginia
  46. Richmond, Virginia
  47. Middleton, Wisconsin
ALL GENDERS
13 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study to Assess the Long-Term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder
Official Title  ICMJE A Randomized, Double-Blind, Placebo-Controlled Study of Continuation Treatment With Xanax XR in the Treatment of Adolescents With a Primary Diagnosis of Panic Disorder
Brief Summary The purpose of this study is to evaluate the long-term (6-month) efficacy, safety, and tolerability of alprazolam XR in adolescents with panic disorder.
Detailed Description Due to recruitment difficulties in this adolescent population, the clinical program for alprazolam XR was cancelled and this study was terminated on 1 September 2004. There were no safety concerns that led to this decision.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Panic Disorder
Intervention  ICMJE
  • Other: placebo
    Patients continued taking the matching placebo that they were taking when they completed Study A6131002 (oral tablets taken once daily).
  • Drug: alprazolam XR
    Patients continued taking the same dosage of alprazolam that they were taking when they completed Study A6131002 (oral tablets taken once daily (1-6mg)); patients taking less than 6 mg/day who failed to show a satisfactory clinical response since the previous visit, and who were free of dose-limiting adverse events, could have their dosage titrated upward by 1 mg/day; upward daily dosage titration of 1 mg was allowed every 7 days, up to a maximum daily dosage of 6 mg/day; patients who were unable to tolerate the previous dosage level of alprazolam XR could have their daily dosage reduced.
    Other Name: Xanax XR
Study Arms  ICMJE
  • Placebo Comparator: Placebo group
    Intervention: Other: placebo
  • Active Comparator: Alprazolam XR group
    Intervention: Drug: alprazolam XR
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: March 5, 2008)		3
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE September 2004
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • A primary Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision diagnosis of panic disorder with or without agoraphobia based on the Mini-International Neuropsychiatric Interview for Children and Adolescents
  • Subjects with an average of 1) at least one 4-symptom panic attack per week over the last 4 weeks before screening; 2) at least one 4-symptom panic attack per week over the last 4 weeks before baseline; and 3) at least one 4-symptom panic attack in the 7 days prior to baseline
  • To enter Study A6131007, subjects must have completed Study A6131002, had an acceptable tolerability to study drug, and in the clinical judgment of the investigator, could have benefited from continued study treatment.

Exclusion Criteria:

  • Subjects must continue to meet all of the exclusion criteria enumerated in the Acute Efficacy Study (Protocol A6131002) with the following exception: Subjects will be allowed to undergo cognitive-behavioral or other panic-specific therapy and any other psychotherapy (e.g., supportive and/or family therapy) during the expected study period in this study.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 13 Years to 17 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00635076
Other Study ID Numbers  ICMJE A6131007
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP